Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Rate of Favorable Pathologic Response (FPR)
Study Overview
Brief Summary
The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •For women of childbearing potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 52 weeks after the end of radiation.
- •For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner 52 weeks after radiation.
- •Agreement to adhere to Lifestyle Considerations (as outlined in protocol) throughout study duration.
- •Pathologically (histologically or cytologically) proven diagnosis of high-grade (grade 2 or 3) Soft Tissue Sarcoma (STS) of the deep trunk and/or extremity. Clinical evidence should be documented, and may consist of pathology or imaging, and should be sufficient to estimate the size of the primary (for T stage)
- •Primary site deemed resectable prior to the start of trial
- •American Joint Committee on Cancer (AJCC) 8th edition staging T1-4 N0 M0, no evidence of distant metastases
- •Patients must have clinically or radiographically evident measurable disease at the primary site.
- •Pre-Radiation Therapy (RT) MRI within 4 weeks of the start of RT.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to
- •Deemed a surgical candidate
- •Participant agrees to blood and plasma preservation for future analysis.
Exclusion Criteria
- •Contraindications to an MRI
- •Positive urine pregnancy test
- •Gross total excision of primary STS, including an unplanned excision
- •Superficial sarcoma located primarily in the subcutaneous or cutaneous tissue
- •Prior radiation to the region of the study cancer that would result in overlap of radiation therapy fields.
- •Participants with a medical condition or social situation that, at the discretion of the principal investigator, would preclude them from completion of the trial.
Arms & Interventions
Treatment
Participants will receive pretreatment diagnostic MRIs to generate MRI habitats (images of tumor regions/subregions in different sequences). These images will identify radioresistant cells within the tumor to allow for more precise and higher doses of radiation to the resistant cells.
Participants will then be treated with neoadjuvant external beam radiation by using the intensity modulated radiation (IMRT) technique, with dose painting (simultaneous integrated boost/SIB) to 70 Gray Units (Gy), 60 Gy, and 50 Gy in 25 fractions for habitats 1, 2, and 3, respectively.
Intervention: Intensity Modulated Radiation Therapy (IMRT) (Radiation)
Treatment
Participants will receive pretreatment diagnostic MRIs to generate MRI habitats (images of tumor regions/subregions in different sequences). These images will identify radioresistant cells within the tumor to allow for more precise and higher doses of radiation to the resistant cells.
Participants will then be treated with neoadjuvant external beam radiation by using the intensity modulated radiation (IMRT) technique, with dose painting (simultaneous integrated boost/SIB) to 70 Gray Units (Gy), 60 Gy, and 50 Gy in 25 fractions for habitats 1, 2, and 3, respectively.
Intervention: MRI (Diagnostic Test)
Outcomes
Primary Outcomes
Rate of Favorable Pathologic Response (FPR)
Time Frame: Week 10
Percentage of participants with Favorable Pathologic Response (FPR): tumor necrosis \>/= 95% at time of surgery. FPR is associated with improved R0 resection rates, local control, distant control, and overall survival. Therefore, FPR acts as an early surrogate for outcome.
Secondary Outcomes
- Percentage of tumor with clear margin and positive margin(Weeks 10-13)